Chimeric Therapeutics (ASX:CHM) Beta: -0.3267 (As of Jun. 24, 2026)


What is Chimeric Therapeutics Beta?

Chimeric Therapeutics ASX:CHM +1.47% Beta is -0.3267 as of Jun. 24, 2026. The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Chimeric Therapeutics's Beta is -0.3267.

Chimeric Therapeutics  (ASX:CHM) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Chimeric Therapeutics Beta Related Terms

Chimeric Therapeutics Beta Historical Data

* Premium members only.

The historical data trend for Chimeric Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chimeric Therapeutics Beta Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Beta
0.00 0.00 0.00 2.00 1.95

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 2.00 2.06 1.95 1.26

ASX:CHM vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Chimeric Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's Beta falls into.


Chimeric Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.3267 mean?
Chimeric Therapeutics (ASX:CHM) has a Beta of -0.3267 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Chimeric Therapeutics and its competitors.
Is Chimeric Therapeutics' Beta too high?
Chimeric Therapeutics' current Beta is -0.3267.
How does Chimeric Therapeutics' Beta compare to VRTX and REGN?
Chimeric Therapeutics' Beta of -0.3267 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Chimeric Therapeutics and its competitors. Chimeric Therapeutics's current Beta is -0.3267. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (ASX:CHM) has a current Beta of -0.3267. The current Beta is -0.3267. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Chimeric Therapeutics (ASX:CHM), the current Beta is -0.3267 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chimeric Therapeutics Business Description

Address 62 Lygon Street, Level 3, Carlton, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.